开立医疗(300633) - 2025 Q3 - 季度财报

Revenue and Profitability - Q3 2025 revenue reached ¥495,046,605.15, a 28.42% increase compared to ¥385,505,275.46 in the same period last year[5] - Net profit attributable to shareholders was ¥13,519,199.57, down 78.05% from ¥61,587,550.89 year-on-year[5] - Total operating revenue for the current period reached ¥1,459,311,230.15, an increase of 4.4% compared to ¥1,398,196,592.81 in the previous period[21] - Net profit for the current period was ¥33,511,062.11, a decrease of 69% compared to ¥108,985,799.47 in the previous period[22] - Basic earnings per share decreased to -¥0.0312, a decline of 78.09% from -¥0.1424 in the same period last year[5] - Basic earnings per share decreased to ¥0.0774 from ¥0.2520 in the previous period, reflecting a significant decline in profitability[23] - The total comprehensive income for the current period was ¥43,270,305.45, down from ¥111,317,494.35 in the previous period, indicating a decline in overall financial health[23] Cash Flow and Financial Position - The net cash flow from operating activities was ¥380,972,060.00, a significant increase of 1,294.04% compared to ¥31,906,075.99 in the previous year[5] - Cash flow from operating activities decreased to ¥1,453,350,399.53 from ¥1,500,680,815.11, indicating a decline in cash generation from core operations[25] - Operating cash inflow totaled $1,620,769,293.86, a decrease from $1,694,856,768.64 in the previous period[26] - Operating cash outflow increased to $2,001,741,353.86 from $1,662,950,692.65, resulting in a net cash flow from operating activities of -$380,972,060.00 compared to $31,906,075.99 previously[26] - Cash paid to employees increased to $713,772,007.99 from $651,268,066.41[26] - Cash paid for other operating activities rose to $367,302,857.01 from $301,322,900.11[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,116,016,210.53, a decrease of 4.57% from ¥4,312,997,155.23 at the end of the previous year[5] - Total current assets decreased from CNY 2,974,995,087.77 to CNY 2,673,062,414.67, a reduction of about 10.1%[16] - Total liabilities decreased to ¥996,867,693.17 from ¥1,204,774,675.82, indicating a reduction in financial obligations[22] - Short-term borrowings decreased from CNY 262,207,517.28 to CNY 224,260,541.20, a reduction of about 14.5%[18] - Accounts payable decreased from CNY 331,545,887.07 to CNY 304,032,262.04, a decline of approximately 8.3%[18] Inventory and Investments - Inventory increased by 38.13% to ¥902,073,900.00, attributed to increased stockpiling[8] - The company reported a 96.68% decrease in trading financial assets, with a balance of ¥14,556,100.00 compared to the beginning of the year[8] - Investment income rose by 183.53% to ¥2,078,200.00, mainly due to increased returns from financial products[10] - Cash flow from investing activities increased by 176.08% to ¥325,548,400.00, reflecting reduced cash outflows related to investments[11] Shareholder Information - Total number of common shareholders at the end of the reporting period is 16,131[13] - The top two shareholders, Chen Zhiqiang and Wu Kunxiang, each hold 22.12% of shares, totaling 95,725,200 shares[13] Other Financial Metrics - The company reported a financial expense of -¥38,303,603.88, which is an increase in net financial income compared to -¥27,355,896.24 in the previous period[22] - Other comprehensive income after tax for the current period was ¥9,759,243.34, significantly higher than ¥2,331,694.88 in the previous period, reflecting improved financial performance in this area[23] - The company has a goodwill of CNY 110,530,076.89, slightly down from CNY 112,506,143.69[18] - The company has no preferred shareholders or related matters to report[15]